KORU Medical Systems (NASDAQ:KRMD) Issues Earnings Results, Beats Expectations By $0.04 EPS

KORU Medical Systems (NASDAQ:KRMD) posted its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04, FiscalAI reports. KORU Medical Systems had a negative return on equity of 10.63% and a negative net margin of 4.03%. The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.33 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q3 revenue grew 11% to $11.6 million, though growth slowed as expected amid international timing effects. On a normalized basis, domestic core revenue grew 10% and international core grew 23%; management expects high-teens growth in Q4.
• Profitability and margins improved: gross margin rose 500 basis points year over year to 65.2%, and the company reported its second consecutive quarter of positive net income, alongside progress in adjusted EBITDA.
• KORU raised its 2026 outlook: revenue guidance is now $48 million–$48.5 million, gross margin guidance is 63%–64%, and the company expects positive full-year adjusted EBITDA and year-end cash above $8 million.
• Commercial and product initiatives broaden potential growth: new distribution agreements in Europe and Africa, three specialty pharmacies dispensing KORU products for RYSTIGGO home administration, and progress on drug programs and the Freedom360 pump could expand reach, though several opportunities remain subject to partner timelines and regulatory review.

KORU Medical Systems Stock Up 20.7%

Shares of KORU Medical Systems stock traded up $0.66 on Wednesday, hitting $3.81. The stock had a trading volume of 332,569 shares, compared to its average volume of 185,422. KORU Medical Systems has a twelve month low of $2.86 and a twelve month high of $6.61. The business’s 50 day moving average is $3.12 and its two-hundred day moving average is $3.95. The stock has a market cap of $175.22 million, a price-to-earnings ratio of -95.38 and a beta of 0.47.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Craig Hallum reiterated a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a report on Thursday, August 6th. Piper Sandler reissued a “neutral” rating and issued a $4.50 price objective (down from $5.00) on shares of KORU Medical Systems in a research report on Wednesday. Zacks Research cut shares of KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 30th. Weiss Ratings cut shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 29th. Finally, Wall Street Zen downgraded shares of KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.50.

Insider Buying and Selling at KORU Medical Systems

In other news, insider Adam Kalbermatten purchased 32,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was acquired at an average cost of $3.16 per share, with a total value of $101,120.00. Following the acquisition, the insider owned 394,017 shares in the company, valued at approximately $1,245,093.72. This trade represents a 8.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 18.50% of the company’s stock.

KORU Medical Systems News Roundup

These are some of the KRMD news items that stood out recently:

• Positive Sentiment: KORU reported third-quarter EPS of $0.02, ahead of the $0.02-per-share loss analysts expected. Revenue of $11.57 million also topped the $11.33 million consensus. Earnings report
• Positive Sentiment: The company forecast FY 2026 revenue of $48.0 million to $48.5 million, slightly above the $48.0 million consensus at the midpoint of its range. It also aims to end the year with cash above $8 million. 2026 revenue outlook and cash target
• Negative Sentiment: Piper Sandler reaffirmed its “neutral” rating but reduced its price target to $4.50 from $5.00, tempering the positive earnings news. Piper Sandler ratings

KORU Medical Systems Company Profile

KORU Medical Systems, Inc. develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems. KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.